EFEMP2

Across TCGA pan-cancer cohorts, EFEMP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EFEMP2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EFEMP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFEMP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where EFEMP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	56	view →
LSCC	DFS	Median	II,III,IV	0.540	0.838	.003	20	view →
UCEC	DFS	Tertile	II,III,IV	0.485	0.916	.032	16	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.913	.019	5	view →
LUAD	OS	Tertile	II,III,IV	0.511	0.919	.046	3	view →
GBM	DFS	Tertile	All	0.635	0.814	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EFEMP2–CCRCC (DFS)

Open the CCRCC breakdown →